Arcus Biosciences, Inc.
CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
Last updated:
Abstract:
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.
Status:
Application
Type:
Utility
Filling date:
16 Jun 2021
Issue date:
23 Dec 2021